Oculis Holding AG (OCS)
| Market Cap | 676.95M -29.1% |
| Revenue (ttm) | 1.40M +49.9% |
| Net Income | -117.93M |
| EPS | -2.15 |
| Shares Out | 60.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 871,780 |
| Open | 11.67 |
| Previous Close | 11.83 |
| Day's Range | 11.17 - 12.05 |
| 52-Week Range | 11.17 - 34.48 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 38.01 (+239.07%) |
| Earnings Date | May 11, 2026 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $38.01, which is an increase of 239.07% from the latest price.
News
Oculis price target lowered to $23 from $42 at JPMorgan
JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating on the shares. The firm cites the negative Phase 3 diabetic macular…
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Oculis Holding AG (NASDAQ: OCS) or certain of its executive officers violated federal securities laws. The in...
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares. The firm updated its model following news its OCS-01…
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares.
Oculis price target lowered to $35 from $44 at BofA
BofA lowered the firm’s price target on Oculis (OCS) to $35 from $44 and keeps a Buy rating on the shares. The firm removed OCS-01 in DME from its model…
Oculis price target lowered to $38 from $46 at Needham
Needham lowered the firm’s price target on Oculis (OCS) to $38 from $46 and keeps a Buy rating on the shares.
Oculis price target lowered to $45 from $75 at Guggenheim
Guggenheim lowered the firm’s price target on Oculis (OCS) to $45 from $75 and keeps a Buy rating on the shares after the company reported that the Phase 3 DIAMOND-1…
Oculis price target lowered to $26 from $47 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $26 from $47 and keeps a Buy rating on the shares. Results from the two Phase 3 DIAMOND trials…
Oculis price target lowered to $40 from $50 at Stifel
Stifel lowered the firm’s price target on Oculis (OCS) to $40 from $50 and keeps a Buy rating on the shares after the company halted further development for OCS-01 in…
Oculis Holding AG Transcript: Study result
Phase III trials of OCS-01 in DME failed to meet primary and key secondary endpoints, despite showing significant retinal thickness reduction and a favorable safety profile. No FDA filing will be pursued, and resources will shift to late-stage assets Privosegtor and licaminlimab.
Oculis Holding AG Press release: Study result
Oculis Holding AG issued a press release on May 29, 2026, disclosing material business information to investors.
Oculis Holding AG Slides: Study result
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Oculis Holding AG trading resumes
16:21 EDT Oculis (OCS) Holding AG trading resumes
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial...
Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met
Oculis (OCS) Holding announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema. The DIAMOND program consisted of two…
Oculis Holding AG trading halted, news pending
14:43 EDT Oculis (OCS) Holding AG trading halted, news pending
Oculis quickly falls 26% to $22 per share
Oculis (OCS) shares have plunged $7.65, or 26% to $22.00 in afternoon trading.
Oculis initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Oculis (OCS) with a Buy rating and $75 price target The firm sees OCS-01 having the potential to become the first non-invasive topical treatment for DME,…
Oculis price target raised to $42 from $38 at JPMorgan
JPMorgan raised the firm’s price target on Oculis (OCS) to $42 from $38 and keeps an Overweight rating on the shares. The firm expects topline results in a joint disclosure…
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May...
Oculis Holding AG Transcript: AGM 2026
The meeting approved all agenda items, including financial statements, board elections, compensation, and capital increases. Clinical programs advanced significantly, with major trial readouts expected in 2026 and 2027. Net loss increased due to R&D investment.
Oculis Holding AG Slides: FY 2026
Oculis Holding AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 13, 2026.
Oculis price target raised to $47 from $44 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $47 from $44 and keeps a Buy rating on the shares. Oculis reported Q1 results and completed Phase 3…
Oculis price target raised to $44 from $43 at BofA
BofA raised the firm’s price target on Oculis (OCS) to $44 from $43 and keeps a Buy rating on the shares following the company’s Q1 update.